Browse products
Biotechnological innovations in the pharmaceutical industry in Poland 2009Development forecasts for biotechnology sector for 2009-2011
|
Polish version also available »
Our clients say...
This raport is now available in a special offer!
“As a London-based company, with operations abroad, we looked for the best-in-class Market Intelligence supplier. PMR brought us quality reports that improved our CEE market knowledge and understanding.”
Development Manager, GVA Grimley
“PMR reports are a serious contribution to the market overview picture, focusing our attention on key events in the industry as well as highlighting both general and specific market indicators. Together, these components are the base for our future forecasts of construction market development and help us to plan our sales.
”
Market Analyst, Alpha Cement
“It's a great pleasure to cooperate with PMR because of its analysts' wealth of experience in understanding the local market. We consider PMR a competent and professional company which helps us conduct our business. I would also like to state that PMR's team is always ready to respond to emerging customer needs. We can recommend it as a reliable partner.”
Business Analyst, Hilti Distribution, Russia
“PMR's analysts understand our needs well and the standard of their service has always fully met our expectations. We are looking forward to cooperating with PMR in the future as well. ”
Senior Trade and Investment Adviser, British Embassy in Warsaw
“We consider PMR a competent and professional company. PMR analysts understand our needs clearly and their services have fully met our expectations. I strongly recommend the company as a reliable partner in providing economic information and market analysis.”
General Manager, Sanofi-Synthelabo
“PMR provides a good service and is always open to discussion. All reports are well structured & are always on time.”
Member of the Managment Board, SCA Hygiene Products
“We use PMR's services due to their analysts' extensive experience in market analysis, their high quality and level of engagement in the market research carried out for us. We consider PMR a competent and professional company and recommend them as a reliable partner in the area of economic information and market analysis.”
Senior Trade and Investment Adviser, British Embassy in Warsaw
“Sanofi-Aventis group regularly order PMR's reports and newsletters concerning the Polish pharmaceutical market. We use PMR's services because of the wealth of experience of its analysts in undertaking market analysis and a high level of quality and involvement in the field of market research. ”
General Manager, Sanofi-Synthelabo
Find out more
Biotechnological innovations in the pharmaceutical industry in Poland 2009 provides a comprehensive overview of the biotechnology market in Poland. Covering major industry trends and events, it touches on both domestic and international occurrences that have significance to the Polish market. The report also investigates the size of the market and the most important innovations relevant to the pharmaceutical sector in recent years. From an operational point of view, the report profiles the major players active on the Polish market, as well as the legislative setting they face. A directory of the 20 largest biopharmaceutical companies and developmental forecasts up to 2011 is included.
The report also comprises:
- the value of biotechnology market Polish pharmaceutical industry
- details on Polish biotech firms investing in development of domestic and international market
- data on niche biotech market segments in Poland
- key players on the market profiles
- undergoing investments in Poland
- legislation briefing regarding biotechnology market in Poland
Biotechnological innovations in the pharmaceutical industry in Poland 2009 was prepared using PMR MarketInsight Methodology.
Request sample pages/interactive screenshare
Report methodology
Executive summary
Overview of the Polish market of pharmaceutical biotechnology
- Key events and trends in the biotechnology sector in Poland
- Key trends and events in 2007-2009
- Events and trends anticipated for 2009-2011
- Key characteristics of the Polish market of biotechnology in pharmaceutics
- Value of the Polish market of pharmaceutical biotechnology 2003-2011
Biotech firms in Poland
- Foreign investment on the Polish pharmaceutical biotechnology market
- Number and classification of Polish biotech firms
- Overview of the largest biotech firms on the Polish pharmaceutical market
- Biotech companies connected with the pharmaceutical industry
Selected biotechnological innovations of the Polish pharmaceutical industry
- Stem cell therapy: Celther
- siRNA-based innovative biotech drug: Celon Pharna
- Modified monoclonal antibody therapy: Mabion
- Tissue engineering and regenerative medicine: Euroimplant
- Innovative vaccines against skin and kidney cancer: Biocontract
- Innovative platform for the development of biotech drugs: Adamed
- Innovation at the point of contact between science and industry: Biotechnology and Antibiotics Institute
- Biotech innovations leading to the development of new pharmaceutical substances
- Advanced molecular diagnostics for clinical trials: Read-Gene
- New technologies for the development of biotech drugs: BioCentrum
- Innovative screening and comparative research to find bioactive compounds: Proteon Pharmaceuticals
- BioIT as support for the development of innovative drugs: Selvita
Factors material to the development of biotechnology in Poland
- Human resources
- Opinions about biotechnology in medicine
- Legislative environment
- Key regulations
- Act on genetically modified organisms
- Patent law
- Legislative support for innovation
- Quality standards in the Polish biotech sector
- Initiatives supporting the development of innovation and technology transfer
- Science & technology and industrial parks
- General overview
- Current tenants from biotechnology in pharmaceutics and related fields in selected technology parks in Poland
- Clusters
- EU funding for the development of biotechnology innovations
- Access to higher risk capital
List of graphs
List of tables
About PMR
Contact PMR
List of graphs
- Value (PLN m) and y-o-y growth of the Polish market of pharmaceutical biotechnology, 2003-2011 12,
- Bioton’s revenues (PLN m) and revenue y-o-y change, 2003-2008
- Bioton’s net financial result (PLN m), 2003-2008
- Bioton’s revenues and net financial result (PLN m), Q1 2008 and Q1 2009
- IBSS Biomed’s revenues (PLN m) and y-o-y revenue change in Poland, 1998-2007
- IBSS Biomed’s net profit (PLN m) and net profit y-o-y change in Poland, 1998-2007
- Biomed Lublin’s revenues (PLN m) and revenue y-o-y change in Poland, 1998-2008
- Biomed Lublin’s net financial result (PLN m) in Poland, 1998-2008
- Polfa Tarchomin’s sales value structure, 2007
- Polfa Tarchomin’s domestic sales value structure, 2008
- Polfa Tarchomin’s revenues (PLN m) and revenue y-o-y change, 1998-Q1 2009
- Polfa Tarchomin’s net financial result (PLN m), 1998-Q1 2009
- Percentage shareholdings in Mabion of Poland, 2009
- Euroimplant’s net financial result (PLN’000) in Poland, 2007-2008
- Biocontract’s financial results (PLN m) in Poland, 2007
- Adamed’s revenues (PLN m) and revenue y-o-y change in Poland, 1999-2008
- Adamed’s net financial result (PLN m), 1999-2008
- Read-Gene’s net financial result (PLN’000) in Poland, 2005-2009
- Forecast for Read-Gene’s revenue and net profit structure in Poland, 2009
- BioCentrum’s revenues (PLN m) and revenue y-o-y change in Poland, 2004-2007
- BioCentrum’s net profit (PLN’000) and net profit y-o-y change in Poland, 2004-2007
- Number of candidates to biotechnology and biomedical engineering specialisation in Poland, 2006-2008
- Projected demand for graduates of natural science specialisations in next 5 and 15 years (number of selections of Voivod Labour Offices) in Poland, December 2008
- Assessment of results of use of modern biotechnological methods in Poland
- Poles’ opinion on use of biotechnology to produce new drugs and vaccines
- Opinions on the statement “research into drugs and vaccines to be used in biotechnology and genetic engineering comprise a threat to the environment or human life”
- Applications for closed use of GMOs in projects with applications in medicine and pharmaceutics in Poland, 2002-H1 2009
- Number of applications for closed GMO use by biotech firms of the pharmaceutical industry in Poland, 2002-H1 2009
List of tables
- Structure of Bioton Capital Group, 2008
- The most important science and technology parks which have as a priority direction the support of the development of biotechnological companies in Poland, 2009
- Selected biotechnology-related cluster initiatives relevant to the pharmaceutical and related industries in Poland, 2009
- Companies and institutions from the biopharmaceutical and related sectors, which have received financing from the Innovative Economy Operational Programme and project value in Poland, 2009
Biotechnological innovations in the pharmaceutical industry in Poland 2009
Development forecasts for biotechnology sector for 2009-2011
Choose your version of this product:
| Language / Licence | Single | 5 Users | Corporate | Global |
| English or Polish | 2000€ | 3000€ | 4000€ | 5000€ |
| English and Polish | 2800€ | 4200€ | 5600€ | 7000€ |
Compare licences
- - for the product preservation: saving the product in the memory of one computer belonging to the client;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for the individual use of one person only, who is indicated by the client during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of 2 to 5 computers belonging to the organisation indicated by the client while purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for 2 to 5 people who work for the organisation indicated by the client during purchasing process, and who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers must be located in the same country as the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in the same country as the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.
- - for the product preservation: saving the product in the memory of an unlimited number of computers belonging to the organisation indicated by the client during purchasing process; these computers can be located in or outside of the country of the organisation indicated during purchasing process;
- - for multiplying and making the product available: multiplication of the product by production of its copies either by printing or by digitalisation (e.g. on a disc, CD-ROM, DVD, magnetic tape, magneto-optic carrier, print and electronic devices, including electronic paper) for an unlimited number of people who work for the organisation indicated by the client during purchasing process, who are in or outside of the country of the organisation indicated during purchasing process.
Any other preservation, multiplication, copying and dissemination etc. which is beyond the scope of this licence is strictly forbidden.